I currently lead Pfizer-sponsored global Phase I–III trials at ICON Strategic Solutions across more than 15 countries, accountable for timelines, budgets, data quality, and ICH-GCP compliance from feasibility through database lock.
I've delivered oncology, rare disease, vaccine, cardiovascular, infectious disease, immunology, and respiratory studies, while building risk-adjusted monitoring strategies, leading study start-up, and maintaining zero critical findings across multiple FDA, EMA, and local-authority inspections.
I line-manage global CRA, aCRA, and CTA teams and partner with CROs, vendors, sites, and cross-functional stakeholders to resolve risk early. My MBA and prior financial-analysis experience strengthen my budgeting, forecasting, reconciliation, and vendor-negotiation work.

